Close Menu

NEW YORK – NeoGenomics announced Tuesday a 51 percent year-over-year uptick in its third quarter revenues, with growth in both its clinical services and pharma services businesses. 

For the three months ended Sept. 30, total revenues reached $104.7 million, up from $69.1 million in Q3 2018. It beat the analysts' average estimate of $99.1 million.

Organic revenue growth was greater than 20 percent, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.